Analyst Joseph Pantginis of H.C. Wainwright maintained a Buy rating on VYNE Therapeutics (VYNE – Research Report), reducing the price target to $4.50.
Joseph Pantginis has given his Buy rating due to a combination of factors related to VYNE Therapeutics’ ongoing clinical developments. Despite the recent clinical hold on the VYN202 Phase 1b trial for plaque psoriasis due to observed testicular toxicity in animal studies, Pantginis remains optimistic about VYNE’s overall prospects. The company is actively working with the FDA to resolve the issue, and importantly, no serious adverse events have been reported in the human subjects enrolled so far.
Additionally, Pantginis highlights the promising progress of VYNE’s repibresib gel, which is currently in a Phase 2b trial for nonsegmental vitiligo. The trial is progressing without interruption and aims to evaluate the safety and efficacy of the treatment. The previous Phase 1b trial showed encouraging results, and Pantginis believes that repibresib has a strong potential for success in treating vitiligo. These factors contribute to his positive outlook and Buy rating for VYNE’s stock.
Pantginis covers the Healthcare sector, focusing on stocks such as Viking Therapeutics, Cytokinetics, and Lexicon Pharmaceuticals. According to TipRanks, Pantginis has an average return of -19.8% and a 22.78% success rate on recommended stocks.